普健生物(武汉)科技有限公司

首页 产品目录 产品目录(简版) 公司动态 企业认证 企业体检 公司相册 联系我们

武汉艾必赛生物有限公司推荐Anti-HeV/NiV Glycoprotein G Antibody (HENV-26),精品抗体

发布人:普健生物(武汉)科技有限公司

发布日期:2026/2/3 15:20:46

链接https://www.abinscience.cn/product/68/14511.html

名称:Anti-HeV/NiV Glycoprotein G Antibody (HENV-26)

货号:VK685033

种属反应性:Hendra virus (isolate Horse/Autralia/Hendra/1994) & Nipah virus

宿主:Mouse

形式:Liquid

纯度:>95% as determined by SDS-PAGE.

克隆性:Monoclonal

同种型:IgG1, kappa

应用:ELISA, FCM, Neutralization

Accession号 O89343, Q9IH62

靶点:G, Glycoprotein G, Attachment glycoprotein, Receptor binding protein, RBP

用途范围:仅用于科研

储存:Use  a manual defrost freezer and avoid repeated freeze-thaw cycles. Store  at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C  long term.


产品介绍:Anti-HeV/NiV  Glycoprotein G Antibody (HENV-26)  是abinScience推出的高特异性小鼠单克隆抗体,靶向亨德拉病毒(HeV)和尼帕病毒(NiV)的G糖蛋白。该抗体经ELISA、流式细胞术(FCM)及中和实验多重验证,具有>95%的高纯度,适用于新发病原体研究、疫苗开发及抗病毒药物筛选等领域。其卓越的亲和力与稳定性为病毒侵入机制研究提供可靠工具,尤其适用于高生物安全等级(BSL-4)相关基础与转化研究。abinScience产品具有亲和力高,灵敏度高,特异性好,稳定性强等优势。



产品购买联系方式:027-87433958/17302791434

邮箱info@abinscience.com

 

参考文献:

1、Architecture and antigenicity of the Nipah virus attachment glycoprotein. PMID: 35239409/

 

2、Structural insights into the Langya virus attachment glycoprotein. PMID: 38815575


3、Investigating  small molecules in propolis as Nipah virus glycoprotein (NiV-G)  inhibitors through molecular interaction studies. PMID: 40051842/

 

4、Therapeutic  administration of a cross-reactive mAb targeting the fusion  glycoprotein of Nipah virus protects nonhuman primates. PMID: 38569014


5、Structure and design of Langya virus glycoprotein antigens. PMID: Update in:/An  attachment glycoprotein nanoparticle elicits broadly neutralizing  antibodies and protects against lethal Nipah virus infection. PMID:  39217188


6、A  highly effective ferritin-based divalent nanoparticle vaccine shields  Syrian hamsters against lethal Nipah virus. PMID: 38911870/

 

7、Evidence  of a potential receptor-binding site on the Nipah virus G protein  (NiV-G): identification of globular head residues with a role in fusion  promotion and their localization on an NiV-G structural model. PMID:  16840334


8、A monoclonal antibody targeting the Nipah virus fusion glycoprotein apex imparts protection from disease. PMID: 39240113/

 

9、Establishing an immune correlate of protection for Nipah virus in nonhuman primates. PMID: 39702562


10、Nipah  virus attachment glycoprotein ectodomain delivered by type 5 adenovirus  vector elicits broad immune response against NiV and HeV. PMID:  37577376/

 

11、In  silico identification of potential drug-like molecules against G  glycoprotein of Nipah virus by molecular docking, DFT studies, and  molecular dynamic simulation. PMID: 36036362


12、Ferritin  nanoparticle-based Nipah virus glycoprotein vaccines elicit potent  protective immune responses in mice and hamsters. PMID: 39293542/

 

13、A  Soluble Version of Nipah Virus Glycoprotein G Delivered by Vaccinia  Virus MVA Activates Specific CD8 and CD4 T Cells in Mice. PMID: 31878180


14、A Hendra virus G glycoprotein subunit vaccine protects African green monkeys from Nipah virus challenge. PMID: 22875827/

 

15、Structural biology of Nipah virus G and F glycoproteins: Insights into therapeutic and vaccine development. PMID: 40261700


16、Identification of the cell binding domain in Nipah virus G glycoprotein using a phage display system. PMID: 28082163/

 

17、Chimeric Fusion (F) and Attachment (G) Glycoprotein Antigen Delivery by mRNA as a Candidate Nipah Vaccine. PMID: 34956199


18、A  Recombinant Chimeric Cedar Virus-Based Surrogate Neutralization Assay  Platform for Pathogenic Henipaviruses. PMID: 37243163/

 

19、Epitope-Based Peptide Vaccine against Glycoprotein G of Nipah Henipavirus Using Immunoinformatics Approaches. PMID: 32377531


20、Distinct  VSV-based Nipah virus vaccines expressing either glycoprotein G or  fusion protein F provide homologous and heterologous protection in a  nonhuman primate model. PMID: 36508878


21、Cysteines  in the stalk of the nipah virus G glycoprotein are located in a  distinct subdomain critical for fusion activation. PMID: 22496210/

 

22、Rhabdovirus-based vaccine platforms against henipaviruses. PMID: 25320306


24、Cell-Free Expression of Nipah Virus Transmembrane Proteins for Proteoliposome Vaccine Design. PMID: 40458951

 

详情请咨询 abinScience 亚洲区官方子公司 —— 武汉艾必赛生物技术有限公司


新闻图片1

新闻图片2

武汉艾必赛生物技术有限公司成立于 2023 年,是 abinScience 在亚洲地区设立的官方全资子公司,全面负责 abinScience 品牌在亚太市场的科研试剂推广、销售及技术支持工作。

依托严格的产品研发体系和国际化的质量管理标准,武汉艾必赛与 AtaGenix、ProteoGenix 等知名品牌保持长期战略合作,现已构建起涵盖抗体、重组蛋白、工具酶、试剂盒、实验耗材在内的多品类供应体系,面向区域内科研机构、高校实验室与生物医药企业,提供稳定、高效、可信赖的产品与服务。

核心业务覆盖
✅ 抗体产品(单抗、多抗、重组抗体等)
✅ 蛋白与多肽试剂(标签蛋白、功能蛋白等)
✅ 分子与细胞实验相关耗材
✅ 定制化研发服务(蛋白表达、抗体定制、亲和力成熟等)
✅ 科研供应链整合与项目配套支持

武汉艾必赛始终秉持“Empowering Bioscience Discovery”的理念,为亚太地区的生命科学研究持续注入高质量动能。


新闻图片3

相关新闻资讯

一文了解特发性炎性肌病(IIM)丨IIM的分类、免疫机制与治疗前沿综述

2026/02/05

特发性炎性肌病(Idiopathic Inflammatory Myopathies, IIM)是一组以骨骼肌慢性炎症和进行性肌无力为核心特征的异质性自身免疫性疾病,常累及皮肤、肺、关节等多系统。其病因复杂,亚型分化显著,尤其当并发间质性肺病(ILD)时,死亡率明显升高,是风湿免疫病学与神经病学领域的研究重点。Figure 1. Manifestations of idiopathic infla

年收益13亿美元疫苗背后:口蹄疫病毒解析与新型VLP疫苗突破

2026/02/04

近日,Diamond Light Source 联合多方研发的新型口蹄疫(FMD)类病毒颗粒(VLP)疫苗引发全球关注——据 CSIL 报告测算,该疫苗若在流行国家实现 20% 市场渗透率,每年可创造 13 亿美元净收益,十年内避免的经济损失高达 110 亿美元。这款疫苗的突破性进展,让口蹄疫这一威胁全球 77% livestock 种群的烈性传染病再次进入公众视野。作为 Picornav

05|信号通路指标系列:NLRP3 炎症小体篇——ASC speck、Caspase-1 与焦亡 readout

2026/02/03

1. NLRP3 炎症小体在“指标库”里的定位NLRP3 inflammasome(NLRP3 炎症小体)是固有免疫与无菌炎症里讨论频率极高的一条通路: 在“第一信号”(priming,例如 Toll 样受体 4–核因子 κB 轴)诱导 NLRP3 与 pro-IL-1β 表达后, “第二信号”(activation,例如三磷酸腺苷、nigericin、单尿酸钠结晶、胆固醇结晶等) 触发 NLRP